Project description
New intranasal drugs against SARS-CoV-2
The extent of the current COVID-19 pandemic demands concerted efforts towards effective diagnostics, therapies and vaccines. In this direction, the EU-funded Fight-nCoV project will accelerate the preclinical development of new broad-spectrum antivirals administered via inhalation. The work builds on ongoing research on drugs that block viral entry and will test their safety and activity against SARS-CoV-2 in a macaque model of the disease. The efficacy information on these intranasal inhibitors in non-human primates will lay the foundation for the next step in the development pipeline of these drugs for human use.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
10691 Stockholm
Sweden
See on map
Participants (5)
75015 Paris 15
See on map
89081 Ulm
See on map
8000 Aarhus C
See on map
751 03 Uppsala
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
45141 Essen
See on map